<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935854</url>
  </required_header>
  <id_info>
    <org_study_id>48527</org_study_id>
    <secondary_id>OTF005</secondary_id>
    <nct_id>NCT03935854</nct_id>
  </id_info>
  <brief_title>Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Schizophrenia or Bipolar Illness</brief_title>
  <official_title>Impact of A Low-Carbohydrate, High-Fat, Ketogenic Diet on Obesity, Metabolic Abnormalities and Psychiatric Symptoms in Patients With Schizophrenia or Bipolar Illness: An Open Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Obesity Treatment Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To initiate a low-carbohydrate, high-fat (LCHF) ketogenic dietary intervention among a small
      cohort of outpatients with either schizophrenia or bipolar illness and comorbid
      overweight/obesity currently taking psychotropic medications.

      Adults with mental illness represent a high-risk, marginalized group in the current obesity
      epidemic. Among US adults with severe mental illness, obesity and overweight are highly
      prevalent conditions having severe consequences, with patients estimated to die on average 25
      years earlier than the general population largely of premature cardiovascular disease. In
      addition, many psychiatric medications, particularly antipsychotics and mood stabilizers, can
      contribute to metabolic side effects and weight gain. Low-carbohydrate high-fat (LCHF) diets
      have been shown to reduce cardiovascular risk in those with insulin resistance. The purpose
      of this study is to evaluate both the metabolic and psychiatric outcomes with an LCHF diet in
      this psychiatric population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in heart rate from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in weight from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body fat mass from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Hemoglobin A1c from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin resistance measure (HOMA-IR) from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in inflammatory marker (hsCRP) from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lipid profile (triglycerides) from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lipid profile (small dense LDL) from baseline</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lipid profile (HDL) from baseline</measure>
    <time_frame>Baseline,16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Indices - Mood</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Change in Mood Score (Clinical Mood Monitoring) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Indices- Clinical Global Impression</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Change in Clinical Global Impression Scales (CGI) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Indices- Global Assessment of Functioning</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Change in Global Assessment of Functioning (GAF) Scale from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Indices- Quality of Life</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Change in Manchester Quality of Life Scale (MANSA) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Indices- BPRS</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Change in Brief Psychiatric Rating Scale (BPRS) from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <condition>Ketogenic Dieting</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Schizophrenia</condition>
  <condition>Weight Gain</condition>
  <condition>Psychotropic Drug, Unspecified Causing Adverse Effects in Therapeutic Use</condition>
  <arm_group>
    <arm_group_label>Ketogenic Diet 16 Week Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LCHF, Ketogenic Diet</intervention_name>
    <description>Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks</description>
    <arm_group_label>Ketogenic Diet 16 Week Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-70 years old

          2. Meet DSM V criteria for schizophrenia or bipolar disorder, any subtype, for &gt; 1 year
             and clinically stable (with no hospitalization for past 3 months)

          3. Currently taking psychotropic medication and gained at least 5% weight since starting
             medication or have a BMI greater than or equal to 26 kg/m2 or presence of at least one
             metabolic abnormality (hypertriglyceridemia, insulin resistance, dyslipidemia,
             impaired glucose tolerance)

          4. Willing to consent to all study procedures and attend follow-up appointments and
             motivated to follow the dietary program.

          5. Sufficient control over their food intake to adhere to study diets.

          6. Willingness to regularly monitor blood pressure, glucose, dietary intake, and body
             weight over the 4-month trial

        Exclusion Criteria:

          1. Any subject pregnant or nursing

          2. Comorbidity of developmental delay

          3. Active substance abuse with illicit drugs or alcohol

          4. In a current severe mood or psychotic state when entering the study that would
             prohibit compliance with study visits or dietary program.

          5. Anyone who has been hospitalized or taken clozapine over the past 3 months

          6. Inability to complete baseline measurements

          7. Severe renal or hepatic insufficiency

          8. Cardiovascular dysfunction, including diagnosis of:

               1. Congestive heart failure

               2. Angina

               3. Arrhythmias

               4. Cardiomyopathy

               5. Valvular heart disease

          9. Any other medical condition that may make either diet dangerous as determined by the
             study medical team (e.g. anorexia nervosa)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shebani Sethi Dalai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shebani Sethi Dalai, MD</last_name>
    <phone>650-721-4419</phone>
    <email>shebanis@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kat Nameth, M.S.</last_name>
    <phone>650-721-2168</phone>
    <email>knameth@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Department of Psychiatry &amp; Behavioral Sciences</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kat Nameth Clinical Research Coordinator</last_name>
      <phone>650-721-2168</phone>
      <email>knameth@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Farnaz Hooshmand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Saslow, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Shebani Sethi Dalai</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

